Passage Bio Announces Recipient of Second Annual Tachi Yamada Scholarship Award
May 04 2023 - 7:00AM
Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic
medicines company focused on developing transformative therapies
for central nervous system (CNS) disorders, has announced
Nicolette “Nikki” Evich, a sophomore at The Schreyer Honors College
at The Pennsylvania State University, as the second recipient of
its Tachi Yamada Scholarship award.
The scholarship honors the legacy of Dr. Tachi Yamada,
co-founder and former Chairman of the Passage Bio Board of
Directors and is open to students enrolled in life sciences
programs at four-year colleges and universities in Pennsylvania who
seek a career in the life sciences industry.
Nikki is pursuing a Bachelor of Arts degree with majors in
Pharmacology and Toxicology and has demonstrated exceptional
academic performance by being on the Dean’s List in both her
freshman and sophomore years. She also has a passion for
neuroscience research and is currently working in the Wendy
Hanna-Rose Laboratory at Penn State, where she is studying the
connection between purine metabolism and neurological
disorders.
Her involvement in numerous extracurricular activities,
including the Penn State Special Olympics and Penn State Marathon,
reflects her enthusiasm for helping those in need. Nikki’s
experiences working with special needs children during her high
school years sparked her interest in the life sciences
industry.
“Our team at Passage Bio is thrilled to award the Tachi Yamada
Scholarship to Nikki Evich, whose academic achievements, dedication
to research, and passion for community make her an excellent
recipient for this scholarship,” said William Chou, M.D., chief
executive officer of Passage Bio. “We are confident that Nikki will
continue to make significant contributions to the life sciences
industry, and we are honored to play a small role in helping her
achieve her goals."
Dr. Chou presented the award to Nikki during the Life Sciences
Pennsylvania Annual Awards dinner on May 3, 2023. Through the
scholarship, Nikki will receive financial assistance towards
college-related expenses and will be matched with a Passage Bio
mentor for professional growth opportunities over the two-year
scholarship period.
Passage Bio first announced its plans to launch the annual Tachi
Yamada Scholarship Program in October 2021 to continue the legacy
of Tadataka (Tachi) Yamada, M.D., a visionary biopharma industry
leader who passed away in August 2021. Dr. Yamada had a life-long
devotion to mentoring and building the next generation of
scientists.
About Passage Bio Passage Bio (Nasdaq: PASG) is
a clinical-stage genetic medicines company on a mission to provide
life-transforming therapies for patients with CNS diseases with
limited or no approved treatment options. Our portfolio spans
pediatric and adult CNS indications, and we are currently advancing
clinical programs in GM1 gangliosidosis and frontotemporal dementia
and our preclinical pipeline, including programs in amyotrophic
lateral sclerosis and Huntington’s disease. Based in Philadelphia,
PA, our company has established a strategic collaboration and
licensing agreement with the renowned University of Pennsylvania’s
Gene Therapy Program to conduct our discovery and IND-enabling
preclinical work. Through this collaboration, we have enhanced
access to a broad portfolio of gene therapy candidates and future
gene therapy innovations that we then pair with our deep clinical,
regulatory, manufacturing and commercial expertise to rapidly
advance our robust pipeline of optimized gene therapies. As we work
with speed and tenacity, we are always mindful of patients who may
be able to benefit from our therapies. More information is
available at www.passagebio.com.
For further information, please contact:
Investors:Stuart HendersonPassage
Bio267.866.0114shenderson@passagebio.com
Media:Mike BeyerSam Brown Inc. Healthcare
Communications312.961.2502MikeBeyer@sambrown.com
Passage Bio (NASDAQ:PASG)
Historical Stock Chart
From Apr 2024 to May 2024
Passage Bio (NASDAQ:PASG)
Historical Stock Chart
From May 2023 to May 2024